News stories about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.1329239062474 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at $5.89 on Thursday. Tetraphase Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. During the same quarter in the prior year, the business posted ($0.58) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was up 355.6% compared to the same quarter last year. equities analysts expect that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current year.
Several research analysts recently commented on TTPH shares. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday, August 28th. They set an “overweight” rating and a $14.00 price objective for the company. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 28th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Finally, BMO Capital Markets upped their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $15.15.
In other news, insider Jacques Dumas sold 8,750 shares of the stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total value of $52,762.50. Following the sale, the insider now owns 8,750 shares in the company, valued at $52,762.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director L Patrick Gage acquired 3,880 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the purchase, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The disclosure for this purchase can be found here. Corporate insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Receives News Impact Score of 0.13” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/14/tetraphase-pharmaceuticals-ttph-receives-news-impact-score-of-0-13.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.